Latest Breaking News On - Sciwind biosciences co ltd - Page 1 : comparemela.com

HANGZHOU, China and SAN FRANCISCO, June 9, 2022 /PRNewswire/ Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that two abstracts have been accepted for poster presentations at The International Liver CongressTM 2022, the Annual Meeting of the European Association for the Studies of the Liver (EASL) taking place June 22-26 in London, United Kingdom. During the meeting, data from a combination study of Sciwind's long-lasting GLP-1 peptide analog XW003 and GIP peptide analog XW017 in an obese mouse model and preclinical pharmacology data for the oral small molecule GLP-1 receptor agonist XW014 will be featured in two poster presentations. "We are excited to have an opportunity to present the recent data from our GLP-1 and GIP receptor agonist programs at this prestigious international conference," said Xinle Wu, PhD, Chief Scientific Officer of Sc

United kingdomCity ofXinle wuSciwind biosciences co ltdInternational liver congressInternational liverAnnual meetingEuropean associationChief scientific officerSaturday juneHina and san franciscoJune 9022 prnewswire sciwind biosciences coA clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic diseaseOday announced that two abstracts have been accepted for poster presentations at the international liver congresstm 2022He annual meeting of the european association for studies liver easl taking place june 22 26 in london